Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review.

The American journal of case reports·2026
Same author

Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma.

Haematologica·2026
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity.

Transplantation and cellular therapy·2026
Same author

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Transplantation and cellular therapy·2026
Same author

MRD-guided de-escalation of TBI conditioning in ALL.

Bone marrow transplantation·2026

相关实验视频

Updated: Jan 18, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K

针对扩散型大B细胞淋巴瘤进行最小残留疾病检测.

Miral Atout1, Hadeel Elwaheidi1, Rand Maarouf1

  • 1College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.

Clinical lymphoma, myeloma & leukemia
|May 30, 2025
PubMed
概括

使用循环瘤DNA (ctDNA) 进行的最小残留疾病 (MRD) 测试显示,在扩散性大B细胞淋巴瘤 (DLBCL) 中预测复发有希望. 以ctDNA分析为指导的早期干预可能会改善患者的结果,尽管需要标准化.

关键词:
这就是CAPP-Seqq.循环瘤DNA (ctDNA) 是一种循环瘤DNA.下一代测序 (NGS) 是指下一代的测序.这就是PhasED-Seq.聚合酶连锁反应 (PCR) 是一种

更多相关视频

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.1K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.1K

相关实验视频

Last Updated: Jan 18, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.1K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

12.1K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 分子诊断学 分子诊断学

背景情况:

  • 扩散性大B细胞淋巴瘤 (DLBCL) 在复发和耐药病例中存在重大治疗挑战.
  • 很大一部分DLBCL患者 (35%) 在初始化疗中无法治愈,并且可能复发.
  • 在DLBCL管理中,急需先进的治疗策略和预后工具.

研究的目的:

  • 审查最小残留疾病 (MRD) 测试在预测DLBCL复发中的作用.
  • 要突出循环瘤DNA (ctDNA) 分析作为预后因素的实用性.
  • 探索MRD测试如何为临床决策和治疗策略提供信息.

主要方法:

  • 审查目前的MRD检测技术,包括滴滴数字聚合酶链反应 (DdPCR) 和下一代测序 (NGS).
  • 血液中ctDNA的分析用于MRD评估.
  • 在DLBCL患者中评估MRD的预后值.

主要成果:

  • 检测MRD,特别是ctDNA分析,可以作为一个有价值的临床预后因素.
  • 像DdPCR和NGS这样的技术对于监测治疗反应和评估患者风险至关重要.
  • ctDNA分析表明,有潜力识别患有复发高风险的患者.

结论:

  • ctDNA分析为早期医生干预提供了一个有前途的途径,有可能提高患者的治疗结果和生活质量.
  • 标准化MRD检测技术及其临床整合是必不可少的,但仍然具有挑战性.
  • 需要进一步的研究来克服实施障碍,并优化DLBCL管理的MRD测试.